The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
Abstract
Purpose: To determine whether addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium) to standard gemcitabine therapy improves overall survival in advanced pancreatic cancer. Patients and Methods: This randomized, double-blind, placebo-controlled study compared gemcitabine + tipifarnib versus gemcitabine + placebo in patients with advanced pancreatic adenocarcinoma previously untreated with systemic therapy. Tipifarnib was given at 200 mg bid orally continuously; gemcitabine was given at 1,000 mg/m 2 intravenously weekly × 7 for 8 weeks, then weekly × 3 every 4 weeks. The primary end point was overall survival; secondary end points included 6-month and 1-year survival rates, progression-free survival, response rate, safety, and quality of life. Results: Six hundred eighty-eight patients were enrolled. Baseline characteristics were well balanced between the two treatment arms. No statistically significant differences in survival parameters were observed. The median overall survival for the experimental arm was 193 v 182 days for the control arm (P = .75); 6-month and 1-year survival rates were 53% and 27% v 49% and 24% for the control arm, respectively; median progression-free survival was 112 v 109 days for the control arm. Ten drug-related deaths were reported for the experimental arm and seven for the control arm. Neutropenia and thrombocytopenia grade ≥ 3 were observed in 40% and 15% in the experimental arm versus 30% and 12% in the control arm. Incidences of nonhematologic adverse events were similar in two groups. Conclusion: The combination of gemcitabine and tipifarnib has an acceptable toxicity profile but does not prolong overall survival in advanced pancreatic cancer compared with single-agent gemcitabine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Self-citationBerlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
Rowinsky, E. K., Windle, J. J., & Von Hoff, D. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3631 · Cited by 537
Self-citationKarp, J. E., Lancet, J. E., Kaufmann, S. H., End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3361 · Cited by 443
Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.098 · Cited by 396
Zujewski, J., Horak, I. D., Bol, C. J., Woestenborghs, R., Bowden, C., End, D. W., Piotrovsky, V. K., Chiao, J., Belly, R. T., Todd, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.927 · Cited by 264
Storniolo, A. M., Enas, N. H., Brown, C. A., Voi, M., Rothenberg, M. L., & Schilsky, R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990315)85:6<1261::aid-cncr7>3.0.co;2-t · Cited by 259
Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., & Cheng, J. Q. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.139-148.2000 · Cited by 240
Cited by
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 790
Maitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 683
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Self-citationTargeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Garrido-Laguna, I., & Hidalgo, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 565
Huguet, F., André, T., Hammel, P., Artru, P., Balosso, J., Selle, F., Deniaud-Alexandre, E., Ruszniewski, P., Touboul, E., Labianca, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5663 · Cited by 529
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 451
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Biology and management of pancreatic cancer
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.103333 · Cited by 418
Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., & Smith, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.149 · Cited by 408
Inhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice
Kim, M. P., Evans, D. B., Wang, H., Abbruzzese, J. L., Fleming, J. B., & Gallick, G. E. (2009) · Nature Protocols · doi:10.1038/nprot.2009.171 · Cited by 380
Role of gemcitabine in cancer therapy
Toschi, L., Finocchiaro, G., Bartolini, S., Gioia, V, & Cappuzzo, F. (2005) · Future Oncology · doi:10.1517/14796694.1.1.7 · Cited by 373
Infante, J. R., Somer, B. G., Park, J. O., Li, C.-P., Scheulen, M. E., Kasubhai, S. M., Oh, D.-Y., Liu, Y., Redhu, S., Steplewski, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 370
Wang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 340
Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., Zimmermann, A., John, W., Von Hoff, D., Arning, M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi309 · Cited by 306
Self-citationNovel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Basso, A. D., Kirschmeier, P., & Bishop, W. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500012-jlr200 · Cited by 297
Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., & Maitra, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0152 · Cited by 296
Therapeutic Advances in Pancreatic Cancer
Paulson, A. S., Tran Cao, H. S., Tempero, M. A., & Lowy, A. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.078 · Cited by 290
Pancreatic Cancer: Basic and Clinical Aspects
Schneider, G., Siveke, J. T., Eckel, F., & Schmid, R. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.001 · Cited by 289
Reni, M., Cordio, S., Milandri, C., Passoni, P., Bonetto, E., Oliani, C., Luppi, G., Nicoletti, R., Galli, L., Bordonaro, R., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70175-3 · Cited by 277
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
Monti, D. A., Mitchell, E., Bazzan, A. J., Littman, S., Zabrecky, G., Yeo, C. J., Pillai, M. V., Newberg, A. B., Deshmukh, S., & Levine, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029794 · Cited by 274
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review
Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0405 · Cited by 164
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
Improving prospects for targeting RAS
Singh, H., Longo, D. L., & Chabner, B. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1052 · Cited by 107
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan, N., Boyer, J. L., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1762 · Cited by 102
KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
Shukla, S., Allam, U. S., Ahsan, A., Chen, G., Krishnamurthy, P. M., Marsh, K., Rumschlag, M., Shankar, S., Whitehead, C., Schipper, M., et al. (2014) · Neoplasia · doi:10.1593/neo.14184 · Cited by 96
Richards, D. A., Boehm, K. A., Waterhouse, D. M., Wagener, D. J., Krishnamurthi, S. S., Rosemurgy, A., Grove, W., Macdonald, K., Gulyas, S., Clark, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl081 · Cited by 101
“Marimastat, a matrix metalloproteinase inhibitor [29], and Tipifarnib, a farnesyltransferase inhibitor [30], have both been combined with gemcitabine in large phase III trials.”
BackgroundHayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Rahib, L., Fleshman, J. M., Matrisian, L. M., & Berlin, J. D. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0585 · Cited by 73
Malik, R., Luong, T., Cao, X., Han, B., Shah, N., Franco-Barraza, J., Han, L., Shenoy, V. B., Lelkes, P. I., & Cukierman, E. (2019) · Matrix Biology · doi:10.1016/j.matbio.2018.11.001 · Cited by 74
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
Xie, C., Li, Y., Li, L.-L., Fan, X.-X., Wang, Y.-W., Wei, C.-L., Liu, L., Leung, E. L.-H., & Yao, X.-J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00823 · Cited by 40
Farnesyltransferase inhibitors: where are we now?
Tsimberidou, A. M., Chandhasin, C., & Kurzrock, R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.535516 · Cited by 39
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Long, S.-A., Amparo, A. M., Goodhart, G., Ahmad, S. A., & Waters, A. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402128 · Cited by 31
Thota, R., Maitra, A., & Berlin, J. D. (2017) · Pancreas · doi:10.1097/mpa.0000000000000753 · Cited by 12
Metadata
- Authors
- Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., Safran, H., Humblet, Y., Perez Ruixo, J., Ma, Y., & Von Hoff, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-04-15
- Volume
- 22
- Issue
- 8
- Pages
- 1430-1438
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2129056290
- Cited by
- 786
- References
- 19
- FWCI
- 21.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.